- Home
- LAZR vs GANX Comparison
LAZR vs GANX Comparison
Compare LAZR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZR
- GANX
- Stock Information
- Founded
- LAZR 2012
- GANX 2017
- Country
- LAZR United States
- GANX United States
- Employees
- LAZR N/A
- GANX N/A
- Industry
- LAZR Auto Parts:O.E.M.
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- LAZR Consumer Discretionary
- GANX Health Care
- Exchange
- LAZR Nasdaq
- GANX Nasdaq
- Market Cap
- LAZR 86.0M
- GANX 79.8M
- IPO Year
- LAZR N/A
- GANX 2021
- Fundamental
- Price
- LAZR $0.91
- GANX $3.49
- Analyst Decision
- LAZR Sell
- GANX Strong Buy
- Analyst Count
- LAZR 3
- GANX 6
- Target Price
- LAZR $1.00
- GANX $8.00
- AVG Volume (30 Days)
- LAZR 10.0M
- GANX 1.3M
- Earning Date
- LAZR 11-13-2025
- GANX 11-12-2025
- Dividend Yield
- LAZR N/A
- GANX N/A
- EPS Growth
- LAZR N/A
- GANX N/A
- EPS
- LAZR N/A
- GANX N/A
- Revenue
- LAZR $75,753,000.00
- GANX N/A
- Revenue This Year
- LAZR N/A
- GANX N/A
- Revenue Next Year
- LAZR $12.58
- GANX N/A
- P/E Ratio
- LAZR N/A
- GANX N/A
- Revenue Growth
- LAZR 0.97
- GANX N/A
- 52 Week Low
- LAZR $0.78
- GANX $1.41
- 52 Week High
- LAZR $10.40
- GANX $3.65
- Technical
- Relative Strength Index (RSI)
- LAZR 35.23
- GANX 74.54
- Support Level
- LAZR $0.78
- GANX $2.60
- Resistance Level
- LAZR $1.14
- GANX $3.05
- Average True Range (ATR)
- LAZR 0.12
- GANX 0.34
- MACD
- LAZR 0.01
- GANX 0.06
- Stochastic Oscillator
- LAZR 23.33
- GANX 89.76
About LAZR Luminar Technologies Inc.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.